HealthNovartis ends mid-stage Fabhalta trial for serious kidney condition

Swiss drugmaker Novartis has stopped a mid-stage study of Fabhalta in patients with a serious kidney condition, citing “strategic considerations,” according to a federal clinical trials registry.

NovartisFabhaltaclinical trialkidney disease

RReuters★★☆☆☆2026-10-16 20:10Original